US Stock MarketDetailed Quotes

ANTX AN2 Therapeutics

Watchlist
  • 1.370
  • -0.020-1.44%
Close Nov 27 16:00 ET
  • 1.460
  • +0.090+6.56%
Post 19:53 ET
40.93MMarket Cap-688P/E (TTM)

AN2 Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

AN2 Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

AN2 Therapeutics Earnings Reports

  • AN2 Therapeutics | 8-K: AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

    Nov 13 16:10 ET

  • AN2 Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 13 16:08 ET

  • AN2 Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 13 16:21 ET

  • AN2 Therapeutics | 8-K: AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

    Aug 13 16:08 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 28, 2024

    Buy

    • Buy

      33.33%

    • Hold

      66.67%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data